Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in SDGR.
← Back to Free Index

SDGR

Analysis as of: 2026-08-28
Schrödinger, Inc.
Schrödinger sells computational molecular discovery software to pharma, biotech, industrial, and academic customers and also monetizes collaborative drug discovery programs.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Workflow Ownership Is the Real Upside
The upside case is a cleaner, usage-led discovery software business rather than a binary drug bet. If hosted delivery and Bunsen turn embedded science tools into a program-level control point, value can compound meaningfully; if not, the company stays useful but capped.

Analysis

Thesis
The five-year upside is a business-model upgrade: if hosted delivery, LiveDesign embedding, and Bunsen shift Schrödinger from tool vendor to program-level workflow owner, rising discovery throughput can convert into cleaner recurring software revenue plus selective milestone upside, driving a credible 2x+ equity outcome without needing a single binary drug win.
Last Economy Alignment
AI should expand in-silico discovery demand and Schrödinger owns useful workflow and trust layers with usage-linked pricing, but it does not control the underlying compute bottleneck and can still be bypassed by large customers’ internal stacks.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.9x (from 5 most recent analyses)
Reasoning
I value this as a cleaner recurring discovery-software story with controlled biotech optionality. Hosted delivery should make revenue more durable, Bunsen can expand usage beyond specialist computational chemists, and workflow embedding can lift retention and mix. The upside is meaningful, but it stays in the 2x-5x bucket until management proves repeatable expansion beyond a few flagship accounts and shows that AI raises paid control, not just feature usage.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is value capture, not scientific relevance. Schrödinger likely remains useful in AI-era drug discovery, but the equity case weakens if hosted delivery mainly changes accounting, if Bunsen lifts usage without lifting paid workflow control, or if concentration and collaborator lumpiness keep revenue too uneven for a durable rerating.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.44
They sit inside the software workflows scientists use to design molecules, so cheaper AI can make those workflows run more often and on more programs. The risk is that big drug companies keep the main control layer in-house and use Schrödinger as a useful engine instead of paying it to own the workflow.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$21.43
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case